ClinicalTrials.gg
CompletedNCT04459338Updated Jun 9, 2023Results posted

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

A Phase 3 interventional study of Exendin-9,39 and Saline in Healthy, sponsored by Adrian Vella. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-09.

Sponsored by Adrian Vella · Phase 3, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Study summary

The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study is to evaluate the role of GLP1R in the response to elevated glucagon concentrations.

Read the detailed description

Glucagon within the islet can signal the β-cell through GLP1R, and acts as an insulin secretagogue. This signaling is blocked by exendin-9,39. The relative importance of glucagon signaling through its cognate receptor or through GLP1R is unknown. Despite the lower affinity of GLP1R for glucagon, intra-islet concentrations of glucagon are sufficiently high to stimulate GLP1R. The other situation where this may occur is in response to pharmacologic doses of glucagon as used for β-cell function testing or raising peripheral glucagon concentrations above fasting values. The experiments proposed will characterize the role of GLP1R in glucagon's actions on the β-cell and the potential therapeutic role of dual (GLP-1R and glucagon receptor) agonists for the treatment of T2DM and obesity.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Adrian Vella is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 weight-stable, non-diabetic subjects

Exclusion criteria

Exclusion Criteria:

  • Age \< 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
  • ≥5.9%
  • Use of glucose-lowering agents.
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or .
  • Symptomatic macrovascular or microvascular disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Saline, Then Exendin-9,39

    A week or two after screening, participants were admitted to the CRTU and Saline was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused. After completion of this study participants underwent a washout period of 2 weeks after which they were readmitted to the CRTU and Exendin-9,39 was infused at 300pmol/kg/min was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused.

    Biological: Exendin-9,39 · Other: Saline

  • Experimental
    Exendin-9,39, Then Saline

    A week or two after screening, participants were admitted to the CRTU and Exendin-9,39 was infused at 300pmol/kg/min during a hyperglycemic clamp during which escalating doses of glucagon were infused. After completion of this study participants underwent a washout period of 2 weeks after which they were readmitted to the CRTU and Saline was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused.

    Biological: Exendin-9,39 · Other: Saline

Interventions

  • BiologicalAvexitideStudies of AvexitideAvexitide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor

  • OtherSaline

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Insulin Secretion Rate During Exendin-9,39 Infusion vs. Insulin Secretion Rate During Saline Infusion

    This is the area under the curve for insulin secretion over the duration of the hyperglycemic clamp (0 to 300 minutes during the study in the Clinical Research Unit).

    Time frame: Area under the curve was quantified at the end of the Saline Study and at the end of the Exendin-9,39 study

07

Results

Posted Jun 9, 2023

Participant flow

Healthy volunteers responded to intramural advertising at the Mayo Clinic between March 2021 and September 2021

Participant flow — Overall Study
MilestoneSaline, Then Exendin-9,39Exendin-9,39, Then Saline
Started56
Completed46
Not completed10
Withdrew: Loss of iv during study10

Outcome measures

PrimaryInsulin Secretion Rate During Exendin-9,39 Infusion vs. Insulin Secretion Rate During Saline Infusion

This is the area under the curve for insulin secretion over the duration of the hyperglycemic clamp (0 to 300 minutes during the study in the Clinical Research Unit).

Time frame:
Area under the curve was quantified at the end of the Saline Study and at the end of the Exendin-9,39 study
Reported as:
Mean · nmol/min per 300 min
Insulin Secretion Rate During Exendin-9,39 Infusion vs. Insulin Secretion Rate During Saline Infusion
nmol/min per 300 minInsulin Secretion During the Saline StudyInsulin Secretion During the Exendin-9,39 Study
Insulin Secretion Rate During Exendin-9,39 Infusion vs. Insulin Secretion Rate During Saline Infusion191 ± 23171 ± 19
Statistical analysis
  • Insulin Secretion During the Saline Study vs Insulin Secretion During the Exendin-9,39 Study · t-test, 2 sided · p = 0.02

Adverse events

Collected over Time between screening and completion of the study = 6 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saline0/11 (0%)0/11 (0%)2/11 (18.2%)
Exendin-9,390/11 (0%)0/11 (0%)0/11 (0%)
Most frequent other events
Most frequent other events
EventSalineExendin-9,39
Infusion line lostSkin and subcutaneous tissue disorders1/110/11
NauseaGastrointestinal disorders1/110/11

Baseline characteristics

Subjects without diabetes to enable evaluation of insulin secretory capacity

Age, Categorical
Age, Categorical(Participants)All Participants
<=18 years0
Between 18 and 65 years11
>=65 years0
Age, Continuous
Age, Continuous(years)All Participants
Mean26 ± 3
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female9
Male2
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)All Participants
Region of Enrollment
Region of Enrollment(participants)All Participants
United States11
08

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jun 2022, 15 months.

Results were first posted in Jun 2023, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 7, 2020
StartActual
Mar 4, 2021
Primary completionActual
Jun 14, 2022
CompletionActual
Jun 14, 2022
Results first posted
Jun 9, 2023
Last update
Jun 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04459338
Lead sponsor
Adrian Vella
Responsible party
Adrian Vella (Principal Investigator, Mayo Clinic) — Sponsor-investigator
First posted
Jul 7, 2020
Start date
Mar 4, 2021
Primary completion
Jun 14, 2022
Completion
Jun 14, 2022
Results posted
Jun 9, 2023
Last update
Jun 9, 2023

Study contacts

Adrian Vella, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avexitide

Start the discussion